Vasoconstriction to polymorphonuclear leukocytes in the isolated, perfused rabbit heart: Inhibition by prostacyclin mimetics

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 5, 1996, Pages 680-685

  Rossoni, Giuseppe ^a   Sala, Angelo ^a   Buccellati, Carola ^a   Maclouf, Jacques ^b   Folco, Gian Carlo ^a   Berti, Ferruccio ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Defibrotide; Iloprost; Leukocyte endothelial cell adhesion; Polymorphonuclear leukocyte; Sulfidopeptide leukotrienes; Transcellular metabolism

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CALCIMYCIN; DEFIBROTIDE; ILOPROST; LYSINE ACETYLSALICYLATE; PEPTIDOLEUKOTRIENE; POLYDEOXYRIBONUCLEOTIDE; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RABBIT; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; CORONARY VESSELS; HUMANS; ILOPROST; NEUTROPHILS; PERFUSION; POLYDEOXYRIBONUCLEOTIDES; RABBITS; VASOCONSTRICTION; VENTRICULAR FUNCTION, LEFT;

EID: 0029961627     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199605000-00010     Document Type: Article

References (46)

1. Dahlen SE, Bjork J, Hedqvist P, et al. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules; in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78:3887-91.
2. 4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986;261:16466-72.
3. 4 by human platelets. J Biol Chem 1988;263: 174-81.
4. Marcus AJ, Broekman MJ, Safier LB, et al. Formation of leukotrienes and other hydroxy-acids during platelet-neutrophil interactions in vitro. Biochem Biophys Res Commun 1982;109:130-7.
5. 4 by transcellular biosynthesis. Proc Natl Acad Sci USA 1986;83:1349-53.
6. Maclouf J, Murphy RC, Henson P. Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells. Blood 1989;74: 703-7.
7. Feuerstein G. Autonomic pharmacology of leukotrienes. J Auton Pharmacol 1985;5:149-68.
8. 4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 1982;217:841-3.
9. Evers AS, Murphree S, Saffitz JE, et al. Effects of endogenously produced leukotrienes, thromboxane and prostaglandins on coronary vascular resistance in rabbit myocardial infarction. J Clin Invest 1985;75:992-9.
10. Sala A, Rossoni G, Buccellati C, et al. Formation of sultidopeptide-leukotrienes by cell-cell interaction causes coronary vasoconstriction in isolated, cell-perfused heart of rabbit. Br J Pharmacol 1993;110:1206-12.
11. Kloner RA, Giacomelli F, Alker KJ, et al. Influx of neutrophils into the walls of large epicardial coronary arteries in response to ischemia/reperfusion. Circulation 1991;84:1758-72.
12. Lucchesi BR, Mullane KM. Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol 1986;26:201-24.
13. Schror K. Cytoprotective properties of prostacyclin. In: Rubanyi GM, Vane J, eds. Prostacyclin: new perspectives for basic research and novel therapeutic indication. Amsterdam: Elsevier, 1992:157-68.
14. Vane J, Botting R. Prostacyclin in perspective. Crit Ischaemia 1993;3(suppl 1):4-13.
15. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259-94.
16. Berti F, Rossoni G, Magni F, et al. Non-steroidal antiinflammatory drugs aggravate acute myocardial schemia in perfused rabbit heart; a role for prostacyclin. J Cardiovasc Pharmacol 1988;12:438-44.
17. Harlan JM. Leukocyte-endothelial interactions. Blood 1985;65: 513-25.
18. Hickman P, McCollum PT, Belch JJF. Neutrophils may contribute to the morbidity and mortality of claudicants. Br J Surg 1994;81: 790-8.
19. Schlant RC, Forman S, Stamler V, et al. The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. The 5-year findings of the Coronary Drug Project. Circulation 1982;66:401-14.
20. Lowe GDO, Machado SG, Krol WF, et al. White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. Thromb Haemost 1985;54:700-3.
21. Friedman GD, Klatsky AL, Siegelaub AB. The leukocyte count as a predictor of myocardial infarction. N Engl J Med 1974;290: 1275-8.
22. Belch JJF. The white blood cell as a risk factor for thrombotic vascular disease. Vasc Med Rev 1990;1:203-13.
23. Sala A, Aliev GM, Rossoni G, et al. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood 1996 (in press).
24. 4 on the guinea-pig isolated heart. J Physiol 1981;317:94-5.
25. Belch JJF, Saniabadi A, Forbes CD. The effect of ZK36374 (iloprost) on white cell behaviour. In: Schror K, Gryglewski RJ, eds. Prostacyclin and its stable analogue iloprost. Berlin: Springer, 1986:97-102.
26. Ferrari R, Cargnoni A, Ceconi C, et al. Protective effect of a prostacyclin-mimetic on the ischaemic-reperfused rabbit myocardium. J Mol Cell Cardiol 1988;20:1095-106.
27. Berti F, Rossoni G, Biasi G, et al. Defibrotide, by enhancing prostacyclin generation, prevents endothelin-1 induced contraction in human saphenous veins. Prostaglandins 1990;40:337-50.
28. Berti F, Rossoni G, Bianchi G, et al. Effect of defibrotide on prostacyclin release from isolated rabbit kidneys and protection from post-ischemic acute renal failure in vivo. Eicosanoids 1991; 4:209-15.
29. Bitterman H, Lefer DJ, Lefer AM. Novel mechanism of action of a prostacyclin enhancing agent in haemorrhagic shock. Naunyn Schmiedebergs Arch Pharmacol 1988;337:679-86.
30. Berti F, Rossoni G, Della Bella D, et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 1993;22:321-6.
31. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 1987;60:666-73.
32. Smith EF III, Gallenkamper W, Beckman R, et al. Early and late administration of PG12 analogue, ZK 36374: effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 1984;18:163-73.
33. De Langen CD, Van Gilst WH, Wesseling GH. Sustained protection by iloprost of the porcine heart in the acute and chrome phases of myocardial infarction. J Cardiovasc Pharmacol 1985;7:924-8.
34. Hohfeld T, Strobach H, Schror K. Stimulation of endogenous prostacyclin protects the reperfused pig myocardium from ischemic injury. J Pharmacol Exp Ther 1993;264:397-405.
35. Thiemermann C, Lobel P, Schror K. Usefulness of defibrotide in protecting ischemic myocardium from early reperfusion damage. Am J Cardiol 1985;56:978-82.
36. Schror K, Thiemermann C, Lobel P. Stimulation of vascular prostacyclin formation by defibrotide: a new strategy for treatment of acute myocardial ischaemia. In: Schmutzler H, Rutsch W, Dougherty FC, eds. Limitation of infarct size. Berlin: Springer-Verlag, 1989:83-93.
37. Thiemermann C, Thomas GR, Vane JR. Defibrotide reduces infarct size in a rabbit model of experimental myocardial ischemia and reperfusion. Br J Pharmacol 1989;97:401-8.
38. Boxer LA, Allen JM, Schmidt M, Yoder M, Baehner RL. Inhibition of polymorphonuclear leukocyte adherence by prostacyclin. J Lab Clin Med 1980;95:672-8.
39. Higgs GA, Moncada S, Vane JR. Prostacyclin reduces the number of "slow moving" leukocytes in hamster cheek pouch venules. J Physiol 1978;280:55-6P.
40. Tang DG, Grossi IM, Chen YQ, Diglio CA, Honn KV. 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of alpha V beta 3 integrins on endothelial cells. Int J Cancer 1993;54:102-11.
41. Fauler J, Frolich C. Cardiovascular effects of leukotrienes. Cardiovasc Drugs Ther 1989;3:499-505.
42. Sasaki K, Ueno A, Katori M, Kikawada R. Detection of leukotriene B4 in cardiac tissue and its role in infarct extension through leucocyte migration. Cardiovasc Res 1988;22:142-8.
43. Cooper DR, Kelliher GJ, Kowey PR. Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. Am Heart J 1988;116:1194-200.
44. Toki Y, Hieda N, Torii T, et al. The effects of lipoxygenase inhibitor and peptido-leukotriene antagonist on myocardial injury in a canine coronary occlusion-reperfusion model. Prostaglandins 1988;35:555-71.
45. Hashimoto H, Miyazawa K, Hagiwara M, Miyasaka K, Nakashima M. Beneficial effects of a new 5-lipoxygenase inhibitor on occlusion- and occlusion-reperfusion-induced myocardial injury. Arzneimittel Forschung Drug Res 1990;40:126-9.
46. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992;85:230-6.